| abstract |
A stable aqueous pharmaceutical composition for subcutaneous or intramuscular administration to a subject, wherein the composition comprises natalizumab at a concentration of 120 to 190 mg / ml, a phosphate buffer at a concentration of 5 mM to 30 mM, sodium chloride at a concentration between 100 mM and 200 mM, and polysorbate 80 in an amount of 0.01% to 0.1% (w / v), and where the composition has a pH 5.5 to pH 6.5, and where natalizumab comprises the sequence of light chain amino acids of SEQ ID NO: 1 and the heavy chain amino acid sequence of SEQ ID NO: 2. |